Influenza vaccine, adjuvanted - Biologic Drug Details

Summary for influenza vaccine, adjuvanted

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for influenza vaccine, adjuvanted

Recent Clinical Trials for influenza vaccine, adjuvanted

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Taiwan University Hospital	NA
Seqirus	Phase 2
Seqirus	Phase 2/Phase 3

See all influenza vaccine, adjuvanted clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for influenza vaccine, adjuvanted Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for influenza vaccine, adjuvanted Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	10,220,155	2026-07-17	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	10,357,616	2037-11-17	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	10,376,652	2037-02-24	DrugPatentWatch analysis and company disclosures
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	11,097,063	2039-01-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for influenza vaccine, adjuvanted Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	11,013,795	2036-06-24	Patent claims search
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	9,821,051	2031-10-21	Patent claims search
Seqirus Inc.	FLUAD,FLUAD QUADRIVALENT	influenza vaccine, adjuvanted	Injection	125510	11,013,795	2036-06-24	Patent claims search
Seqirus Inc.	FLUAD,FLUAD QUADRIVALENT	influenza vaccine, adjuvanted	Injection	125510	9,821,051	2031-10-21	Patent claims search

International Patents for influenza vaccine, adjuvanted

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006079481
Canada	2584762
Brazil	PI0919925
Austria	E499962

Supplementary Protection Certificates for influenza vaccine, adjuvanted

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132017000073676	Italy		PRODUCT NAME: INSULINA ASPART A RAPIDA AZIONE(FIASP); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1160, 20170111
300880	Netherlands		PRODUCT NAME: SNELWERKENDE INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
CA 2017 00026	Denmark		PRODUCT NAME: CERTIFIKAT; REG. NO/DATE:
2017C/024	Belgium		PRODUCT NAME: SNELWERKENDE INSULINE ASPART; AUTHORISATION NUMBER AND DATE: EU/1/16/1160 20170111

Market dynamics and financial trajectory for the biologic drug: Influenza vaccine, adjuvanted

Last updated: April 25, 2026

What does “adjuvanted influenza vaccine” mean for the market?

Adjuvanted influenza vaccines are seasonal flu immunizations that include an immune-stimulating ingredient designed to improve immunogenicity and often enable dose-sparing, expanded indications, or stronger responses in populations with weaker immunity (older adults, vaccine-naïve groups, and certain risk populations). In commercial practice, “adjuvanted” typically denotes formulations that use established adjuvant technologies and are priced at a premium versus unadjuvanted flu vaccines in many markets, with reimbursement and tender frameworks largely determining realized net price.

Commercial dynamics for adjuvanted flu vaccines are shaped by four factors:

• Seasonal demand cycles (annual procurement windows, inventory build, and seasonality-driven consumption).
• Public-sector tendering and private payer formularies (selection tends to hinge on clinical differentiation plus price and supply reliability).
• Portfolios across age cohorts and risk indications (older-adult and chronic disease programs are major demand anchors).
• Supply and manufacturing capacity for influenza antigens and adjuvant supply (bottlenecks can shift market share in the short term).

Which financial signals matter most for adjuvanted seasonal influenza vaccines?

Financial trajectory in this category is driven by:

• Annual unit demand and uptake in targeted cohorts (coverage rates in 65+ and high-risk groups).
• Net price realization (gross price less rebates, tender concessions, and distribution economics).
• Mix shift between adjuvanted and standard formulations as payers and governments optimize procurement.
• Competitive substitution between adjuvanted brands and rival adjuvant platforms.

For investors and R&D planners, the key “look-through” metrics are:

1. Sales growth stability across seasons (less about year-to-year volatility and more about whether adjuvanted share grows or is capped).
2. Pricing power within tenders (whether adjuvanted premiums persist once competing bids mature).
3. Share stability vs. switching costs in national immunization programs.
4. Cycle-to-cycle manufacturing continuity (any supply constraints can cause lasting procurement reallocations for multiple seasons).

How do market dynamics play out in the adjuvanted influenza segment?

1) Public-sector procurement dominates volume and shapes price

In most major geographies, influenza vaccine demand is pulled by government or insurer procurement. Adjuvanted vaccines typically win when:

• Programs target older adults and require stronger immune responses.
• Health technology assessment frameworks accept the clinical and economic case.
• Tender processes value dose schedule, immunogenicity, and safety, and when supply assurances reduce operational risk.

Procurement structure impacts margins: realized prices compress when multiple manufacturers bid aggressively, but adjuvant differentiation can preserve pricing if payers prioritize efficacy-in-the-field and program continuity.

2) Private markets react to clinical evidence and payer coverage

Private payers and provider networks typically decide based on formulary coverage and out-of-pocket patient cost. Adjuvanted products often command premium uptake when:

• They are the only reimbursed option in certain clinics or employer programs.
• Physicians recommend them for higher-risk patients.
• Patient demand is supported by insurer coverage policies.

Private markets can grow faster than public markets when reimbursement and patient access improve, but they also exhibit more substitution across brands.

3) Supply constraints can reallocate share fast

Seasonal manufacturing has finite capacity. If an adjuvanted manufacturer faces antigen supply, fill-finish constraints, or adjuvant availability issues, procurement may shift temporarily. The practical result is uneven sales trajectories that can overshoot or undershoot in a single season, followed by normalization if supply stabilizes.

4) Competitive pressure is cyclical, not constant

Influenza vaccines face annual competition. Competitors can gain share during seasons when:

• Their products clear tenders with favorable pricing.
• Their supply is more reliable.
• Their clinical package aligns with program priorities for that season.

The category often shows delayed effects: market share won via one season's tender can persist if program administrators renew preferred supplier status.

What is the financial trajectory pattern investors should expect?

Adjuvanted influenza vaccines generally show:

• Base-year scaling driven by initial category acceptance and formulary inclusion.
• Incremental expansion as programs broaden coverage cohorts or expand tender share to preferred adjuvanted brands.
• Mature-phase stability once a small set of suppliers dominates procurement.
• Seasonal peaks during procurement build and administration period.
• Margin sensitivity to realized net price and sales mix between products and regions.

Because the category is seasonal and tender-led, the “financial trajectory” is less about multi-year blockbuster-style ramp and more about whether the adjuvanted segment gains or loses share relative to unadjuvanted comparators and rival adjuvants.

Where does the evidence base point for adjuvant demand?

Adjuvanted vaccines are positioned to deliver higher immunogenicity than unadjuvanted formulations, with particular emphasis on older adults. Health technology assessments and clinical trial data have repeatedly informed uptake in countries that evaluate immunogenicity and effectiveness in the target population.

Market behavior tends to track reimbursement decisions that incorporate:

• Immunogenicity endpoints (seroprotection/seroresponse metrics and geometric mean titers).
• Safety and tolerability.
• Effectiveness signals in real-world settings where available.
• Economic evaluations (cost per QALY or budget impact).

Those elements translate into procurement preferences that can lock in usage and sustain sales across seasons.

How does this category compare to other flu vaccine segments financially?

A practical comparison framework for business and investment decisions:

• Adjuvanted vs. standard-dose non-adjuvanted: adjuvanted is often higher priced, but volume and mix depend on program willingness to pay.
• Adjuvanted vs. cell-based or recombinant flu vaccines: different geographies use different technology preferences; adjuvanted may win on cost-effectiveness and immune response evidence, while other platforms may compete on supply assurance and procurement compatibility.

The key point: financial outcomes hinge on payer procurement logic, not only on clinical differentiation.

What are the most actionable market dynamics for R&D strategy?

To translate market behavior into R&D and business moves, companies typically pursue one or more of these levers:

1. Broaden label and access within high-value cohorts
   • Older adults, chronic disease programs, and seasonal risk groups.
2. Align with tender evaluation frameworks
   • Provide robust immunogenicity, safety, and health economic dossiers consistent with country decision rules.
3. Stabilize supply chain performance
   • Manufacturing reliability can be as decisive as clinical performance for award renewal.
4. Optimize portfolio sequencing across seasons
   • Track whether switches from rival products lead to durable share or revert next cycle.

What financial trajectory indicators should be monitored season-by-season?

A decision-grade dashboard for adjuvanted influenza vaccines typically includes:

• Total doses supplied and sold by geography
• Net sales and net price per dose (where reported or inferable from disclosed segment economics)
• Share of procurement in major tenders (proxy via government program uptake)
• Sales mix between age groups (particularly 65+ if reported)
• Inventory and returns movements (seasonal dynamics can affect short-term cash flow)
• Supply disruptions or lead-time changes (can shift sales timing and realized pricing)

Key Takeaways

• Adjuvanted influenza vaccines are priced and sold in a seasonal, tender-led environment where realized net price and cohort uptake matter more than headline list price.
• The financial trajectory is primarily determined by market share within high-value programs (often older adults and high-risk groups), procurement renewal behavior, and manufacturing reliability.
• Investors should expect stable, incremental share gains during acceptance phases, followed by maturity-era volatility driven by tender outcomes and supply constraints rather than sustained multi-year ramp typical of chronic biologics.
• R&D and commercial strategy should align with payer evaluation criteria and supply-chain performance because those factors directly influence award renewals and mix.

FAQs

1. How does tendering affect the sales trajectory of adjuvanted influenza vaccines?
   Tender cycles can cause discrete step-changes in volume and net price from one season to the next, with renewal patterns driving multi-season stability.

2. Why do adjuvanted influenza vaccines often hold pricing better than standard vaccines?
   Reimbursement and procurement decisions frequently value immunogenicity and cohort-specific benefit, allowing premiums to persist when clinical and economic dossiers clear HTA thresholds.

3. What is the biggest near-term risk to revenue for this category?
   Manufacturing or supply disruptions that alter procurement allocation and force substitution by governments and insurers for a season or more.

4. Do adjuvanted influenza vaccines behave like blockbuster drugs financially?
   No. Revenue is seasonal and share is governed by annual procurement outcomes, with growth typically driven by incremental uptake and tender wins rather than continuous scaling.

5. What metrics best predict the next season’s performance?
   Current procurement award status in major geographies, order timing and supply readiness, net price trends in tenders, and estimated cohort coverage changes.

References

[1] World Health Organization. Influenza (seasonal). https://www.who.int/health-topics/influenza-(seasonal)
[2] European Medicines Agency. Influenza vaccines (product and evaluation information). https://www.ema.europa.eu/en/medicines
[3] U.S. Food and Drug Administration. Seasonal Influenza Vaccines. https://www.fda.gov/vaccines-blood-biologics/vaccines/seasonal-influenza-vaccines
[4] CDC. Seasonal Flu Vaccine Effectiveness, Recommendations, and Guidance. https://www.cdc.gov/flu/
[5] OECD/WHO or related policy bodies on health technology assessment and immunization program decision-making frameworks (general HTA context). https://www.oecd.org/health/health-technology-assessment/